Rolinsatamab is a chimeric monoclonal antibody of the IgG1κ subtype, specifically designed to target the prolactin receptor (PRLR). This antibody can be conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882 through a cleavable maleimidocaproyl linker, creating the antibody-drug conjugate known as Rolinsatamab talirine. This conjugate features an average of two site-specific drug attachments at engineered cysteines (S239C). The linker incorporates a valine-alanine dipeptide, which serves as a cleavage site for cathepsin B, facilitating the release of the cytotoxic agent upon entry into targeted cells. Rolinsatamab talirine is primarily utilized in therapeutic applications where precise delivery of cytotoxic agents to cells expressing PRLR is required.
Rolinsatamab is a chimeric monoclonal antibody of the IgG1κ subtype, specifically designed to target the prolactin receptor (PRLR). This antibody can be conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882 through a cleavable maleimidocaproyl linker, creating the antibody-drug conjugate known as Rolinsatamab talirine. This conjugate features an average of two site-specific drug attachments at engineered cysteines (S239C). The linker incorporates a valine-alanine dipeptide, which serves as a cleavage site for cathepsin B, facilitating the release of the cytotoxic agent upon entry into targeted cells. Rolinsatamab talirine is primarily utilized in therapeutic applications where precise delivery of cytotoxic agents to cells expressing PRLR is required.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
